damianrasch.com

Pulse Field Ablation for Atrial Fibrillation: A New Approach to Treating AFib

Medically Reviewed & Edited

Board-Certified Invasive Cardiologist
Encinitas and La Jolla, CA

Developed with digital research and writing assistance, then medically reviewed and edited by Dr. Rasch to ensure clinical accuracy and adherence to current evidence-based guidelines.

If you have atrial fibrillation and we have talked about rhythm control options, you have probably heard about catheter ablation. For years, the standard tools for ablation have been radiofrequency energy (heat) and cryogenic freezing (cold). Both work well in the right hands, and I refer many patients for these procedures with excellent results. In the last few years, a genuinely different technology has arrived: Pulse Field Ablation (PFA). It uses electrical pulses to create permanent scar in the atrium, and the early data suggest it may offer a safer and equally effective option for many patients.

This article walks you through what PFA is, how it differs from the older heat-and-cold methods, who is a good candidate, what the trial data actually show, and what the referral experience is like when I send a patient for this procedure. My goal is to give you the real picture so we can make an informed decision together about whether PFA is right for you.

What Pulse Field Ablation Actually Does

The goal of any ablation procedure is the same: create permanent scar tissue in the atrium that blocks the chaotic electrical signals causing AFib. The scar interrupts the abnormal circuits that trigger and sustain AFib, and when it is done correctly, your heart can return to normal rhythm.

In a radiofrequency ablation, the cardiologist uses a catheter with a heated tip to burn the tissue. In a cryoablation, they freeze it. Both approaches have been proven to work over decades. They share a downside: heat and cold damage tissue indiscriminately. They can injure nearby structures you really do not want damaged, like the esophagus that sits right behind the back wall of the left atrium.

PFA works on a completely different principle. Instead of applying heat or cold, it delivers very brief, very high-voltage electrical pulses directly to the heart tissue. Those pulses punch holes in the membranes of the heart muscle cells, a process called irreversible electroporation. The cells cannot recover, they die, and the tissue scars down. The key advantage is that this happens at much lower temperatures than thermal ablation, which means much less collateral damage to nearby structures.

The Physics, Made Simple

The science is worth a paragraph because it explains why PFA is genuinely different from older techniques.

Every cell in your body is wrapped in a membrane that resists ordinary electrical current. When you apply very high-voltage pulses for just microseconds, you cross a threshold and the membrane develops permanent pores. Water and ions rush in. The cell's machinery breaks down and the cell dies. Microsecond pulse PFA, the form used in current clinical devices, produces predominantly necrotic cell death (the cells die and rupture), with some apoptotic component depending on pulse parameters. The dying cells are replaced by scar.

What is remarkable is that this process is not really temperature-dependent the way heat or cold ablation is. The electrical injury kills the cell directly. We can produce reliable, full-thickness scar without heating tissue to 50 or 60 degrees Celsius like radiofrequency does. Temperature-sensitive structures nearby, especially the esophagus, see far less damage.

PFA is not faster than thermal ablation, and it is not intrinsically easier to perform. In theory, and now increasingly in practice, it creates more precise injury with fewer unintended consequences.

FDA-Approved PFA Devices

Several companies have brought PFA systems to market in the United States. The electrophysiologists I refer to have access to these devices.

Farapulse (Boston Scientific) received FDA approval on January 31, 2024, after CE Mark approval in Europe in 2021. It uses a pentaspline-shaped catheter that does both mapping and energy delivery. PulseSelect (Medtronic) uses a circular array catheter that combines mapping and ablation in a single tool, available clinically since 2023 to 2024. Sphere-9 (Affera, now part of Medtronic) is a lattice-tip catheter that can deliver both radiofrequency and pulsed field energy from the same device; the SPHERE Per-AF pivotal trial is ongoing and published pivotal results are not yet available. Varipulse (Johnson & Johnson's Biosense-Webster Irreversible Electroporation Ablation System) is a variable-loop catheter that received FDA clearance after the admIRE pivotal trial.

The choice of device often comes down to what your electrophysiologist is most experienced with and what your specific anatomy looks like. When I refer a patient for PFA, I discuss which device the center typically uses and why.

How PFA Compares to Heat and Cold

The real question is not whether PFA works in theory. It is whether it performs better in practice than the thermal methods we have been using for decades.

On effectiveness, the data are encouraging. The randomized ADVENT trial compared the Farapulse PFA system head-to-head against thermal ablation (either radiofrequency or cryoballoon) in 607 patients with paroxysmal AFib (305 PFA, 302 thermal). At one year, 73.3 percent of PFA patients met the primary effectiveness endpoint versus 71.3 percent for thermal ablation, meeting the noninferiority bar. The much larger MANIFEST-PF European registry followed 1,568 Farapulse patients across 24 centers and found 78.1 percent freedom from atrial arrhythmia at one year (81.6 percent in paroxysmal AFib, 71.5 percent in persistent AFib). Those numbers line up with what we see for high-quality thermal ablation, so PFA is at least as good on effectiveness.

The real advantage shows up in safety. In ADVENT, no PFA patients had esophageal complications and no PFA patients had clinically significant pulmonary vein narrowing, while two thermal patients had persistent diaphragm-paralyzing nerve injuries (both with cryoballoon). Across the largest PFA registries to date (MANIFEST-PF with 1,758 patients, EU-PORIA with 1,233, MANIFEST-17K with 17,642), zero esophageal complications have been reported. That is a striking safety signal compared with thermal ablation, where serious esophageal injury, although rare, can be catastrophic.

What the Major Trials Showed

Let me walk you through the major studies because the data are genuinely good.

The ADVENT trial (Reddy, NEJM 2023) enrolled 607 paroxysmal AFib patients and randomized them to Farapulse PFA or thermal ablation. At one year, 73.3 percent of PFA patients were free of recurrent atrial arrhythmias versus 71.3 percent for thermal ablation. Primary safety events occurred in 2.1 percent of PFA patients versus 1.5 percent of thermal patients, both meeting noninferiority. No esophageal injuries and no clinically significant pulmonary vein narrowing occurred with PFA. Two persistent diaphragm-nerve paralyses occurred in the thermal group, both from cryoballoon. One procedure-related death occurred in the PFA group, from catheter manipulation rather than from the energy itself.

The MANIFEST-PF registry (Turagam, Circulation 2023) followed 1,568 Farapulse patients across 24 European centers. The one-year freedom from atrial arrhythmia was 78.1 percent overall, 81.6 percent in paroxysmal AFib, and 71.5 percent in persistent AFib. Pulmonary vein isolation was achieved in 99.2 percent of patients. Acute serious events occurred in 1.9 percent. Zero esophageal complications. Zero pulmonary vein narrowing. Transient diaphragm-nerve paralysis in 0.46 percent. Persistent diaphragm-nerve palsy in 0.06 percent.

The PULSED AF trial (Verma, Circulation 2023) studied the Medtronic PulseSelect system in 300 patients (150 paroxysmal, 150 persistent). At one year, effectiveness was 66.2 percent for paroxysmal AFib and 55.1 percent for persistent AFib. Serious safety events ran 0.7 percent in both cohorts. No strokes, no esophageal injury, and no pulmonary vein narrowing.

The admIRE trial (Reddy, Circulation 2024) studied the Johnson & Johnson Varipulse catheter in paroxysmal AFib patients across 30 centers. The 12-month effectiveness endpoint was met in 74.6 percent of patients, with one-year freedom from AFib, atrial flutter, or atrial tachycardia at 75.4 percent. Serious adverse events within seven days were 2.9 percent, with pericardial tamponade as the most common complication. Notably, more than a quarter of procedures were performed entirely without fluoroscopy.

The consistent message across these trials: PFA is at least as effective as thermal ablation for paroxysmal AFib and has real safety advantages, especially around the esophagus and pulmonary veins.

Who Is a Good Candidate for PFA

PFA is appropriate for most patients who are candidates for any ablation. Some situations make it especially attractive.

You may be a strong PFA candidate if you have:

You would not be a candidate if you have permanent AFib that we have already decided cannot be reliably converted, severe heart failure with very low ejection fraction, an unstable cardiac condition, an active infection, or anatomy that makes ablation unsafe. Patients with very large atria or extensive scarring need special consideration, and the electrophysiologist will sort that out during the pre-procedure evaluation.

What the Referral Process Looks Like

When I see a patient in clinic who I think might benefit from ablation and PFA is available at the referral center, here is how the conversation goes.

First, I explain what is wrong. Is it paroxysmal AFib or persistent? How symptomatic? What have we tried so far? Then we talk about the options. If you are a good candidate for any ablation, you are likely a good candidate for PFA. I describe the procedure, the recovery, the success rates, and the risks. I make clear that the final decision is one we make together with the electrophysiologist who will perform the procedure.

I refer you to an electrophysiologist I trust, someone who does high volume, who uses modern techniques, and who has experience with PFA if that is the plan. The electrophysiologist takes a full history, often repeats your echocardiogram, looks at recent rhythm tracings, and examines you. They review the technical details of your anatomy and make a final judgment about whether ablation makes sense for you and what approach they would recommend.

If you decide to go ahead, you come back for the procedure. I stay informed of the result, and we follow up to track how you are doing in the months and years afterward. Ablation success depends not just on the procedure but on the long-term follow-up that catches recurrences and adjusts your medications.

What the Procedure and Recovery Are Like

A PFA procedure is performed in an electrophysiology lab by a specialist I refer to. The general flow is similar to any catheter ablation, just with a different energy source.

You arrive fasting in the morning. An IV is started, and you receive sedation. Catheters are advanced through your groin veins to the heart. Using live X-ray and three-dimensional electrical mapping, the electrophysiologist identifies the tissue causing your AFib (usually around the pulmonary veins). The PFA catheter is positioned, and the electrical pulses are delivered. Total time depends on your anatomy and the device, and most procedures take one to two hours.

After the procedure, you spend several hours in recovery while the sedation wears off and the groin sites are watched. Most patients go home the same day or stay overnight. You rest for a few days, avoid heavy lifting, and protect the groin puncture sites.

Recovery is much faster than open-heart surgery. Most patients feel back to normal within a week. Some feel immediate relief from AFib symptoms. Others have a healing period where short irregular rhythms continue temporarily before the heart settles into normal rhythm. That is normal and expected.

Risks and Complications

No procedure is risk-free. I want you to understand what can go wrong, with the reassurance that serious complications are uncommon at high-volume centers.

Esophageal injury. The esophagus runs right behind the left atrium. With thermal ablation, atrioesophageal fistula occurs in roughly 0.02 to 0.1 percent of cases, and lesser thermal injuries are more common. The largest PFA registries to date (MANIFEST-PF, EU-PORIA, MANIFEST-17K) have reported zero esophageal complications. This is one of the strongest safety arguments for PFA over thermal methods.

Diaphragm-nerve injury. The phrenic nerve controls your diaphragm. Injury causes temporary diaphragm paralysis and shortness of breath that usually recovers over weeks to months. In MANIFEST-PF, transient phrenic nerve paralysis occurred in 0.46 percent of PFA patients and persistent palsy in 0.06 percent. In ADVENT, no persistent phrenic palsy occurred with PFA versus two cases in the thermal arm (both with cryoballoon).

Pulmonary vein narrowing. Scar formation near the pulmonary vein openings can gradually narrow them and reduce blood flow from the lungs. Thermal ablation causes pulmonary vein narrowing requiring intervention in under 1 percent of cases. The ADVENT trial found mean PV ostial narrowing of 12.0 percent with thermal ablation versus only 0.9 percent with PFA. Every major PFA registry has reported zero clinically significant PV narrowing.

Cardiac perforation. The catheter can rarely puncture the heart wall, causing bleeding into the sac around the heart. Usually managed with drainage or observation.

Vascular complications. Bleeding, clotting, or pseudoaneurysm at the groin sites occur occasionally. Usually minor and treated conservatively, with surgery rarely needed.

AFib recurrence. Not everyone stays in normal rhythm after ablation. Recurrence rates run roughly 20 to 40 percent at two years depending on whether you count only symptomatic episodes or all monitor-detected ones. If recurrence happens, repeat ablation, rhythm-control drugs, or AV nodal ablation with pacemaker placement may be options.

For most patients, the risk of serious complication is well under 1 percent. The benefit of restored normal rhythm usually outweighs that small risk, especially when AFib is meaningfully impairing your quality of life.

How I Think About This Decision

When I am sitting with a patient who has symptomatic AFib and we are considering ablation, the conversation is not really about whether PFA is perfect. It is about what is best for you in your situation.

If you have tried rate control alone (beta-blockers, calcium channel blockers, digoxin) and it is not enough, and AFib is affecting your life, then rhythm control makes sense. Rhythm-control drugs are an option, and they have their own limitations and side effects. Ablation can be curative or near-curative for many patients.

PFA is genuinely new, which means we have less long-term follow-up data than for radiofrequency or cryoablation. The data we do have are excellent. The effectiveness is comparable to the older methods, the safety profile looks as good or better, and the principle behind it (electrical injury rather than thermal injury) is sound. The electrophysiologists I refer to are experienced with all three approaches and recommend what they think is best for your anatomy and clinical situation.

I do not think PFA will completely replace thermal ablation. Some patients are still better served by radiofrequency or cryo for anatomic or technical reasons. For many patients with paroxysmal or persistent AFib, PFA has earned its place as a first-line rhythm-control option.

The Bottom Line

Pulse Field Ablation is a genuinely new way to treat atrial fibrillation that uses electrical energy instead of heat or cold to create scar tissue and restore normal rhythm. It is based on sound physics, it has been tested in large randomized trials, and the data show it is effective and safe with possible advantages over thermal ablation in terms of esophageal and pulmonary vein protection.

When I refer a patient for PFA, I do so because I believe the chance of success and the favorable safety profile make it worth considering seriously. The final decision, made together with the electrophysiologist who performs the procedure, depends on your specific anatomy, your symptoms, what you have already tried, and your preferences. If ablation is the right choice for you, PFA is absolutely worth discussing with your electrophysiologist.

Frequently Asked Questions

Is PFA better than radiofrequency ablation?

PFA appears to have effectiveness comparable to radiofrequency and a safer profile, especially around the esophagus. Both are very effective treatments. The best approach depends on your anatomy and your electrophysiologist's experience. The clinical trials show PFA is at least as good as radiofrequency for effectiveness with a slightly better safety profile, which makes it a strong choice when available.

Why would you recommend PFA over cryoablation?

Cryoablation is excellent and widely used. PFA may have an advantage in terms of esophageal safety and avoiding pulmonary vein narrowing, and these complications are uncommon with either approach. The choice between PFA and cryoablation usually comes down to what the electrophysiologist is most experienced with and what your anatomy suggests is safest. All three methods work well.

How long have doctors been using PFA for AFib?

PFA systems received FDA approval starting in 2024, so US clinical use is relatively new. Devices were studied in clinical trials for several years before approval, and thousands of patients have had PFA worldwide. We have solid safety and effectiveness data now. Long-term follow-up out to 5 to 10 years is still accumulating.

What is my chance of staying in normal rhythm after PFA?

It depends on your type of AFib, the device, and what is being counted. In paroxysmal AFib, one-year freedom from atrial arrhythmia has been around 73 percent in ADVENT, 75 percent in admIRE, and 82 percent in MANIFEST-PF. In persistent AFib the numbers are lower, around 55 percent in PULSED AF and 72 percent in MANIFEST-PF. Rates trend down over years two and three as minor recurrences accumulate, and how strictly recurrences are counted shifts the numbers. Your individual success rate depends on your AFib type, your anatomy, and the quality of the procedure.

Can I have a repeat ablation if AFib comes back?

Yes. Many patients have successful repeat procedures. Some of the scar from the first ablation is still in place, which can sometimes make the second procedure easier. Success rates for repeat ablation are reasonable, and they tend to be somewhat lower than for first-time procedures. We talk about this with you before the initial procedure.

Will I need to stay on rhythm-control drugs after PFA?

Sometimes yes, sometimes no. Some electrophysiologists discontinue rhythm-control drugs after a successful ablation. Others continue them for a defined period. Your cardiologist and electrophysiologist will decide based on how you respond and how your heart looks on follow-up testing.

How soon after PFA can I exercise?

You are usually asked to rest for a few days and avoid heavy lifting or strenuous activity for one to two weeks to protect the groin sites. Light activity like walking can resume within days. High-intensity exercise typically gets cleared around two to four weeks, depending on your recovery. Your electrophysiologist will give you specific guidance.

What if I am not a candidate for ablation?

Not everyone needs or is a candidate for ablation. If your AFib is well controlled with medications and is not affecting your life, we may simply continue rate control. If ablation is not appropriate for you, other options include better rate control, symptom management, or in selected cases AV nodal ablation with pacemaker implantation to give you a stable rhythm and rate.

References

1. Reddy, Vivek Y., Edward P. Gerstenfeld, Andrea Natale, et al. "Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation (ADVENT)." New England Journal of Medicine 389, no. 18 (2023): 1660-1671.

2. Turagam, Mohit K., Petr Neuzil, Boris Schmidt, et al. "Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry." Circulation 148, no. 1 (2023): 35-46.

3. Verma, Atul, David E. Haines, Lucas V. Boersma, et al. "Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial." Circulation 147, no. 19 (2023): 1422-1432.

4. Reddy, Vivek Y., Hugh Calkins, Moussa Mansour, et al. "Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial." Circulation 150, no. 6 (2024): 503-515.

5. Turagam, Mohit K., Andrea Aryana, John D. Day, et al. "Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients (MANIFEST-US)." Journal of the American College of Cardiology (2026, in press).

6. Joglar, José A., Mina K. Chung, Anastasia L. Armbruster, et al. "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation." Journal of the American College of Cardiology 83, no. 1 (2024): 109-279.

7. Hindricks, Gerhard, Tatjana Potpara, Nikolaos Dagres, et al. "2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with EACTS." European Heart Journal 42, no. 5 (2021): 373-498.

8. Boston Scientific Farapulse PFA System Prescribing Information. 2024.

9. Medtronic PulseSelect PFA System Prescribing Information. 2024.

10. Johnson & Johnson (Biosense Webster) Varipulse Irreversible Electroporation Ablation System Prescribing Information. 2024.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.